Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free AREC Stock Alerts

Arecor Therapeutics (AREC) Competitors

Arecor Therapeutics logo
GBX 69.40 +3.40 (+5.15%)
As of 12:08 PM Eastern
Compare

AREC vs. FARN, MPH, BVXP, 4BB, and ORPH

Should you buy Arecor Therapeutics stock or one of its competitors? MarketBeat compares Arecor Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arecor Therapeutics include Faron Pharmaceuticals Oy (FARN), Mereo BioPharma Group plc (MPH.L) (MPH), Bioventix (BVXP), 4basebio (4BB), and Open Orphan (ORPH). These companies are all part of the "biotechnology" industry.

How does Arecor Therapeutics compare to Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy (LON:FARN) and Arecor Therapeutics (LON:AREC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Arecor Therapeutics has a net margin of 38.74% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat Arecor Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Faron Pharmaceuticals OyN/A 45.13% -70.00%
Arecor Therapeutics 38.74%14.26%-37.31%

In the previous week, Faron Pharmaceuticals Oy had 2 more articles in the media than Arecor Therapeutics. MarketBeat recorded 2 mentions for Faron Pharmaceuticals Oy and 0 mentions for Arecor Therapeutics. Faron Pharmaceuticals Oy's average media sentiment score of 1.14 beat Arecor Therapeutics' score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company Overall Sentiment
Faron Pharmaceuticals Oy Positive
Arecor Therapeutics Neutral

Arecor Therapeutics has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Faron Pharmaceuticals OyN/AN/A-£60.23M-£22.07N/A
Arecor Therapeutics£1.71M15.29-£10.68M£2.0034.70

1.6% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 6.0% of Arecor Therapeutics shares are owned by institutional investors. 3.9% of Faron Pharmaceuticals Oy shares are owned by insiders. Comparatively, 4.8% of Arecor Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Faron Pharmaceuticals Oy has a beta of 1.109, meaning that its share price is 11% more volatile than the broader market. Comparatively, Arecor Therapeutics has a beta of -0.18, meaning that its share price is 118% less volatile than the broader market.

Summary

Arecor Therapeutics beats Faron Pharmaceuticals Oy on 8 of the 12 factors compared between the two stocks.

How does Arecor Therapeutics compare to Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and Arecor Therapeutics (LON:AREC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Mereo BioPharma Group plc (MPH.L) has higher earnings, but lower revenue than Arecor Therapeutics. Mereo BioPharma Group plc (MPH.L) is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A
Arecor Therapeutics£1.71M15.29-£10.68M£2.0034.70

6.0% of Arecor Therapeutics shares are owned by institutional investors. 4.8% of Arecor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Arecor Therapeutics has a net margin of 38.74% compared to Mereo BioPharma Group plc (MPH.L)'s net margin of 0.00%. Arecor Therapeutics' return on equity of 14.26% beat Mereo BioPharma Group plc (MPH.L)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Mereo BioPharma Group plc (MPH.L)N/A N/A N/A
Arecor Therapeutics 38.74%14.26%-37.31%

In the previous week, Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.00 equaled Arecor Therapeutics'average media sentiment score.

Company Overall Sentiment
Mereo BioPharma Group plc (MPH.L) Neutral
Arecor Therapeutics Neutral

Summary

Arecor Therapeutics beats Mereo BioPharma Group plc (MPH.L) on 7 of the 8 factors compared between the two stocks.

How does Arecor Therapeutics compare to Bioventix?

Arecor Therapeutics (LON:AREC) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

6.0% of Arecor Therapeutics shares are owned by institutional investors. Comparatively, 21.1% of Bioventix shares are owned by institutional investors. 4.8% of Arecor Therapeutics shares are owned by insiders. Comparatively, 6.2% of Bioventix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bioventix has higher revenue and earnings than Arecor Therapeutics. Bioventix is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arecor Therapeutics£1.71M15.29-£10.68M£2.0034.70
Bioventix£12.54M6.87£8.12M£140.5211.74

In the previous week, Bioventix had 1 more articles in the media than Arecor Therapeutics. MarketBeat recorded 1 mentions for Bioventix and 0 mentions for Arecor Therapeutics. Arecor Therapeutics' average media sentiment score of 0.00 equaled Bioventix'saverage media sentiment score.

Company Overall Sentiment
Arecor Therapeutics Neutral
Bioventix Neutral

Bioventix has a net margin of 59.30% compared to Arecor Therapeutics' net margin of 38.74%. Bioventix's return on equity of 65.83% beat Arecor Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arecor Therapeutics38.74% 14.26% -37.31%
Bioventix 59.30%65.83%54.07%

Arecor Therapeutics has a beta of -0.18, meaning that its share price is 118% less volatile than the broader market. Comparatively, Bioventix has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

Summary

Bioventix beats Arecor Therapeutics on 10 of the 12 factors compared between the two stocks.

How does Arecor Therapeutics compare to 4basebio?

4basebio (LON:4BB) and Arecor Therapeutics (LON:AREC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

0.9% of 4basebio shares are held by institutional investors. Comparatively, 6.0% of Arecor Therapeutics shares are held by institutional investors. 12.1% of 4basebio shares are held by company insiders. Comparatively, 4.8% of Arecor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

4basebio currently has a consensus target price of GBX 1,600, suggesting a potential upside of 210.68%. Given 4basebio's stronger consensus rating and higher possible upside, research analysts clearly believe 4basebio is more favorable than Arecor Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4basebio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Arecor Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

4basebio has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Arecor Therapeutics has a beta of -0.18, meaning that its stock price is 118% less volatile than the broader market.

In the previous week, 4basebio's average media sentiment score of 0.00 equaled Arecor Therapeutics'average media sentiment score.

Company Overall Sentiment
4basebio Neutral
Arecor Therapeutics Neutral

4basebio has higher earnings, but lower revenue than Arecor Therapeutics. 4basebio is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4basebio£1.69M47.10-£9.84M-£99.00N/A
Arecor Therapeutics£1.71M15.29-£10.68M£2.0034.70

Arecor Therapeutics has a net margin of 38.74% compared to 4basebio's net margin of 0.00%. Arecor Therapeutics' return on equity of 14.26% beat 4basebio's return on equity.

Company Net Margins Return on Equity Return on Assets
4basebioN/A -231.29% -54.30%
Arecor Therapeutics 38.74%14.26%-37.31%

Summary

4basebio and Arecor Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Arecor Therapeutics compare to Open Orphan?

Arecor Therapeutics (LON:AREC) and Open Orphan (LON:ORPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

6.0% of Arecor Therapeutics shares are held by institutional investors. 4.8% of Arecor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Arecor Therapeutics' average media sentiment score of 0.00 equaled Open Orphan'saverage media sentiment score.

Company Overall Sentiment
Arecor Therapeutics Neutral
Open Orphan Neutral

Open Orphan has higher revenue and earnings than Arecor Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arecor Therapeutics£1.71M15.29-£10.68M£2.0034.70
Open Orphan£34.71M0.00N/AN/AN/A

Arecor Therapeutics has a net margin of 38.74% compared to Open Orphan's net margin of 0.00%. Arecor Therapeutics' return on equity of 14.26% beat Open Orphan's return on equity.

Company Net Margins Return on Equity Return on Assets
Arecor Therapeutics38.74% 14.26% -37.31%
Open Orphan N/A N/A N/A

Summary

Arecor Therapeutics beats Open Orphan on 5 of the 7 factors compared between the two stocks.

Get Arecor Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AREC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AREC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AREC vs. The Competition

Export
MetricArecor TherapeuticsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£26.20M£451.60M£6.44B£2.77B
Dividend YieldN/A3.87%2.69%6.12%
P/E Ratio34.703.2023.77365.54
Price / Sales15.296,606.32488.5087,173.10
Price / Cash5.0713.1341.3927.85
Price / Book4.1983.479.767.68
Net Income-£10.68M-£96.07M£3.56B£5.89B
7 Day Performance5.30%-1.70%-3.19%-0.55%
1 Month Performance-0.86%0.74%-0.11%3.15%
1 Year Performance58.30%70.06%25.29%73.57%

Arecor Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AREC
Arecor Therapeutics
N/AGBX 69.40
+5.2%		N/A+55.0%£26.20M£1.71M34.7010
FARN
Faron Pharmaceuticals Oy
N/AGBX 45.40
+6.8%		N/A-80.6%£90.58MN/AN/A34
MPH
Mereo BioPharma Group plc (MPH.L)
N/AN/AN/AN/A£89.76MN/AN/A50
BVXP
Bioventix
N/AGBX 1,700
+1.2%		N/A-42.2%£88.83M£12.54M12.1012
4BB
4basebio
N/AGBX 450
-13.5%		GBX 1,600
+255.6%		-50.3%£69.68M£1.78MN/A101

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:AREC) was last updated on 6/5/2026 by MarketBeat.com Staff.
From Our Partners
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel